Researchers at the University of Oxford have begun the most recent circular of tests for their COVID-19 vaccine in the United States, a step in the race to defeat the coronavirus pandemic.
Oxford researchers, in partnership with AstraZeneca, began measuring the first volunteers in Florida on Friday and 31 Americans won the vaccine or placebo over the weekend as a component of the clinical trial.
“Look at the number of lives lost. And I just don’t need it to continue,” said Jacob Serrano, 23, a trial volunteer, Dr. Jon LaPook, cbs News’s leading medical collaborator.
As the first American to get the vaccine or his oxford and AstraZeneca placebo, Serrano has already lost seven members of his family circle to COVID-19 and says he must be part of the life-saving solution, at all cost.
“I know there’s a threat because it’s like, it’s an attempt,” Serrano said, “but I’d rather get one step closer, no matter what it cost. “
In the third and final phase, the vaccine is tested to determine its protection and efficacy for cutting or blocking COVID-19 symptoms, and approved by the Food and Drug Administration for public use.
Serrano ran Friday, August 28 at the Headlands Jem Research Institute in Lake Worth, Florida. Larry Bush, an infectious disease expert and lead researcher at the site, said he was positive about the effectiveness of the vaccine.
“The immune response is very encouraging,” he said.
In the first stage and at the time of the trials, Bush said the vaccine had shown that “not only do you get physically powerful neutralizing antibodies to fight the coronavirus, but you get a reaction from the T cells. . . to fight the cells that are infected. , very important in the remedy of infections. “
T cells are “another arm of the immune system” that can fight the virus, Bush said.
The University of Oxford has conducted phase 3 trials in the UK, Brazil and South Africa. In earlier stages, there is no evidence that the vaccine caused serious reactions.
Headlands Research stated that its purpose was to recruit members of the Black and Latinx communities that were disproportionately affected by the pandemic.
“The figures imply that these teams of people . . . swelled up at a higher rate,” Bush said. “As a result, this is an organization that would gain great benefits from vaccination. “
AstraZeneca has announced plans to recruit up to 50,000 participants internationally and plans to launch 3 trials in Japan and Russia. The pharmaceutical giant expects to have complex test effects later in 2020.